EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

What market is this report measuring?

Dose Diligence research deskSection 11 · Page 2 of 11Last updated 17 Nov 2026

This report separates four commercial layers:

LayerWhat belongs in itHow the buyer should use it
National medicine marketPharmaceutical purchases, estimated net spending and manufacturer revenueEstablish scale and direction; do not sum incompatible measures
Patient access marketCash-pay offers, insurance cost sharing and manufacturer-linked dispensingModel affordability and the patient journey
Clinic-controlled expenditureStock purchases where applicable, service contracts, integrations, shipping and internal handlingIdentify spending the organization can actually negotiate
Supporting infrastructurePharmacy services, prescription routing, financing, acquisitions and manufacturing investmentMonitor counterparties and potential changes in access arrangements

These are the desk’s analytical categories, not interchangeable accounting measures. The scope includes obesity-focused GLP-1 medicines and related incretin treatments such as tirzepatide; diabetes products appear only where they help explain the wider market.

Evidence labels used below: reported figure; survey estimate; manufacturer-reported estimate; analyst calculation; announced commitment; and not publicly established. Annual data refer to 2025 unless stated otherwise. Recent financial observations cover Q3 2026. Live offer pages were checked on November 17, 2026.

Explore the table row by row

A working view of the research

National medicine market

What belongs in it
Pharmaceutical purchases, estimated net spending and manufacturer revenue
How the buyer should use it
Establish scale and direction; do not sum incompatible measures

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →